1. Scrip

Almirall To Position Oral DMF For Psoriasis Ahead Of EU Biologics Use

 
• By Sten Stovall

Almirall aims to start selling its unpatented fumaric acid derivative throughout Europe in the third quarter for treating plaque psoriasis, but will not seek approval for the medicine in the US.

Psoriasis

Spain-based Almirall SA will roll out its as-yet unpatented fumaric acid derivative throughout Europe in the third quarter of 2017 as a first-line induction and long-term treatment for adults with moderate-to-severe chronic plaque psoriasis, offering, it says, a much cheaper option than new, highly-priced biologic therapies.

The Barcelona-based drug maker is readying plans for EU commercialization of its oral dimethyl fumarate (DMF) treatment after

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Removal Of REMS For CAR-Ts Could Greatly Expand Their Reach

 
• By Alaric DeArment

The FDA eliminated REMS requirements for approved CAR-T cell therapies that have limited their availability, a move that could enable increased use in the community setting.